Nalaganje...
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
Ospemifene is a selective estrogen receptor modulator (SERM), or estrogen receptor agonist/antagonist, that was recently approved by the US Food and Drug Administration for the treatment of dyspareunia associated with vulvar and vaginal atrophy, a chronic condition that affects up to 60% of postmeno...
Shranjeno v:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3792833/ https://ncbi.nlm.nih.gov/pubmed/24109197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJWH.S39146 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|